SAN DIEGO, March 14 /PRNewswire-FirstCall/ -- CryoCor, Inc. , a medical device company focused on the treatment of cardiac arrhythmias, announced today that it will release its financial results for the year ended December 31, 2007 on Thursday, March 20, 2008 after the close of the U.S. financial markets.
CryoCor will also hold a Web cast and conference call at 5:00 p.m. ET / 2:00 p.m. PT on March 20, 2008. Management will discuss the financial results, provide an update on the commercialization of the Company’s Cardiac Cryoablation System for the treatment of right atrial flutter and discuss the Company’s strategic objectives for 2008.
The dial-in numbers are 1-877-407-4018 for domestic callers and 1-201-689-8471 for international callers. A live Web cast of the conference call will be available online from the investor relations page of the Company’s corporate Web site at www.cryocor.com.
After the live Web cast, the call will remain available on CryoCor’s Web site for at least 30 days following presentation. In addition, a telephonic replay of the call will be available. The replay dial-in numbers are 1-877-660-6853 for domestic callers 1-201-612-7415 for international callers. Please use account number 3055 and conference ID number 278655.
About CryoCor
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company’s product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company’s website at http://www.cryocor.com.
nlaudico@theruthgroup.comgtibbitts@cryocor.com zkubow@theruthgroup.comjrando@theruthgroup.com
CONTACT: Gregory J. Tibbitts, Chief Financial Officer of CryoCor,
+1-858-909-2200, gtibbitts@cryocor.com; or investors, Nick Laudico,
+1-646-536-7030, nlaudico@theruthgroup.com, or Zack Kubow, +1-646-536-7020,
zkubow@theruthgroup.com, or media, Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com, all of The Ruth Group for CryoCor
Web site: http://www.cryocor.com/
